



Independent observer  
of the Global Fund

## Round 10 Results, by Country

Based on advice from the TRP, the Board divided eligible Round 10 proposals into five categories, as follows:

- Category 1: Approved proposals requiring no or minor clarifications; any clarifications need to be provided within eight weeks and then given a final approval by the TRP Chair or Vice-Chair.
- Category 2: Proposals that are approved subject to the required clarifications being provided within a limited timeframe (six weeks for the applicant to provide an initial detailed response to the TRP queries, and a further three months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
- Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
- Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in a future round following major revision.
- Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.

The Board approved all proposals in Categories 1, 2 and 2B.

Table 8 provides a summary of the Round 10 results by category. Tables 9 and 10 show the results for each applicant.

Table 8: Round 10 results by category

Category	Number of proposals	TRP-recommended f	
		(Years 1-2)	(Ye
Approved: Category 1	3	\$0.05 b.	\$0.14 b.
Approved: Category 2	49	\$1.03 b.	\$2.73 b.
Approved: Category 2B	27	\$0.65 b.	\$1.85 b.
Subtotal: All Approved Proposals:	79	\$1.73 b.	\$4.72 b.
Not Approved: Category 3	56	\$1.64 b.	\$4.21 b.
Not Approved: Category 4	15	\$0.78 b.	\$2.22 b.
Not Approved: Parts of Category 1, 2 and 2B proposals not recommended for funding *	n/a	\$0.14 b.	\$0.48 b.
Subtotal: All Non-Approved Proposals:	71	\$2.56 b.	\$6.91 b.
Total: All Proposals	150	\$4.30 b.	\$11.63 b.

\* This refers to a situation where a disease proposal with an HSS request attached has been submitted, and the TRP has recommended, and the Board has approved, either the disease proposal or the HSS request, but not both.

Table 9: Round 10 results, by country

Notes:

1. In the following table, DP = disease part.
2. For approved proposals, the costs shown in the last two columns are the amounts recommended by the TRP. For proposals that were not approved, the costs are the amounts requested by the applicant.

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Afghanistan	TB (DP + HSS part)	CCM	Approved	2	€ 16,132,533	€ 23,330,000
Angola	HIV	CCM	Approved	2B	\$25,877,952	\$68,884,900
Angola	Malaria	CCM	Approved	1	\$40,435,549	\$111,239,000
Argentina	HIV MARPs	CCM	Approved	2	\$4,933,812	\$12,500,000
Armenia	HIV MARPs	CCM	Not approved	3	€ 2,328,230	€ 4,817,800
Armenia *	TB (DP)	CCM	Approved	2	€ 3,310,881	€ 8,881,600
Armenia	TB (HSS part)	CCM	Not approved	n/a	€ 1,180,614	€ 2,159,900
Azerbaijan	HIV MARPs	CCM	Not approved	3	\$3,546,724	\$12,466,900
Azerbaijan	Malaria	CCM	Not approved	3	€ 1,880,538	€ 3,571,100
Bangladesh **	TB	CCM	Approved	2B	\$11,677,496	\$98,543,700
Belize	HIV MARPs	CCM	Not approved	3	\$2,602,746	\$6,722,020
Belize	TB	CCM	Not approved	4	\$2,823,065	\$5,960,680
Benin	HIV	CCM	Not approved	3	€ 11,286,254	€ 21,692,000
Benin	TB	CCM	Not approved	3	€ 993,858	€ 2,274,000

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Bosnia & Herz.	HIV	CCM	Not approved	4	€ 2,800,310	€ 5,497,8
Botswana	HIV	CCM	Not approved	3	\$47,926,893	\$137,642
Botswana	TB	CCM	Not approved	3	\$10,828,604	\$25,258,2
Brazil	HIV MARPs	CCM	Not approved	3	\$5,000,000	\$12,500,0
Burkina Faso	HIV (DP)	CCM	Approved	2B	€ 38,993,903	€ 97,448,
Burkina Faso	HIV (HSS part)	CCM	Not approved	n/a	€ 10,272,650	€ 24,384,
Burundi	TB	CCM	Not approved	3	\$4,830,351	\$13,212,8
Cambodia	HIV	CCM	Not approved	3	\$23,124,597	\$47,452,2
Cambodia	TB (DP + HSS part)	CCM	Not approved	3	\$47,313,760	\$132,570
Cameroon	HIV	CCM	Approved	2B	€ 30,200,540	€ 97,411,
Cape Verde	Malaria	CCM	Approved	2B	€ 968,724	€ 1,414,3
Central Af. Rep.	HIV (DP + HSS part)	CCM	Not approved	3	€ 29,077,778	€ 64,570,
Chad	HIV	CCM	Not approved	3	€ 31,801,787	€ 94,985,
Chad	TB (DP + HSS part)	CCM	Not approved	3	€ 11,599,749	€ 22,450,
China	Malaria	CCM	Approved	2B	\$5,830,102	\$15,704,3

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Colombia	TB	CCM	Approved	2B	\$5,390,584	\$11,271,600
Congo Rep.	HIV	CCM	Not approved	3	€ 4,674,974	€ 9,978,900
Congo DR	HIV	CCM	Not approved	3	\$111,533,674	\$295,297,000
Congo DR	Malaria	CCM	Approved	2	\$73,922,870	\$185,122,000
Cote d'Ivoire	HIV (DP + HSS part)	CCM	Not approved	3	€ 57,632,004	€ 133,430,000
Djibouti	TB	CCM	Approved	2	€ 2,461,552	€ 6,080,100
Dominican Rep.	HIV MARPs	CCM	Not approved	4	\$4,950,940	\$12,496,500
Eritrea *	HIV (DP + HSS part)	CCM	Approved	2	\$20,818,140	\$59,897,300
Eritrea * **	TB	CCM	Approved	2B	\$7,316,801	\$22,815,400
Ethiopia	HIV	CCM	Not approved	3	\$88,149,150	\$176,458,000
Ethiopia	Malaria (DP + HSS part)	CCM	Not approved	3	\$97,848,890	\$245,989,000
Ethiopia	TB	CCM	Not approved	3	\$21,107,334	\$82,169,300
Georgia	HIV MARPs	CCM	Approved	2	€ 3,105,210	€ 8,860,000
Georgia	TB	CCM	Approved	2	€ 7,695,603	€ 21,727,000
Ghana	HIV (DP + HSS part)	CCM	Not approved	4	\$499,428,723	\$1,420,130,000

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Ghana *	TB	CCM	Approved	2B	\$31,897,744	\$77,418,400
Guinea	HIV (DP + HSS part)	CCM	Approved	2B	\$20,877,516	\$56,875,400
Guinea	Malaria	CCM	Approved	2B	\$32,046,938	\$46,625,600
Guinea Bissau	HIV (DP + HSS part)	CCM	Not approved	3	€ 26,167,631	€ 63,815,000
Guyana	TB	CCM	Not approved	4	\$486,607	\$1,050,800
Honduras	TB	CCM	Approved	2B	\$6,030,951	\$12,402,400
India	HIV	CCM	Not approved	3	\$21,412,956	\$61,404,000
Indonesia	TB (DP + HSS part)	CCM	Approved	2	\$47,727,271	\$157,544,000
Iran	Malaria	CCM	Approved	2	\$9,363,548	\$19,578,400
Jordan	TB	CCM	Approved	2	\$2,078,829	\$4,666,280
Kazakhstan	HIV MARPs	CCM	Approved	2	\$2,404,755	\$12,449,000
Kenya	HIV	CCM	Approved	2B	\$93,376,285	\$345,103,000
Kenya	Malaria	CCM	Approved	2	\$49,979,579	\$138,370,000
Kyrgyz Rep.	HIV	CCM	Approved	2	\$11,207,840	\$41,480,400
Kyrgyz Rep.	TB	CCM	Not approved	3	\$3,842,777	\$5,659,770

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Lao PDR	TB <small>(HSS part)</small>	CCM	Not approved	n/a	\$8,155,754	\$17,158,000
Lao PDR **	TB <small>(DP)</small>	CCM	Approved	2	\$3,255,999	\$12,887,900
Lesotho	HIV	CCM	Not approved	3	\$29,594,699	\$65,273,200
Liberia	Malaria <small>(DP + HSS part)</small>	CCM	Approved	2	\$28,698,063	\$68,892,600
Liberia	TB	CCM	Approved	2B	\$2,862,226	\$16,061,800
Macedonia	HIV MARPs	CCM	Approved	1	€ 2,825,259	€ 9,407,900
Macedonia	TB	CCM	Approved	2	€ 2,901,528	€ 6,112,700
Madagascar	HIV <small>(DP + HSS part)</small>	CCM	Not approved	3	\$46,050,649	\$110,739,000
Malawi	HIV	CCM	Not approved	3	\$164,254,176	\$561,450,000
Malaysia	HIV MARPs	CCM	Approved	2B	\$4,672,630	\$12,405,200
Maldives	HIV MARPs	CCM	Not approved	3	\$2,880,814	\$8,044,740
Mali	Malaria	CCM	Approved	2B	€ 24,827,735	€ 94,873,000
Mali	TB	CCM	Approved	2	€ 8,053,957	€ 13,773,000
Mauritius	HIV MARPs	CCM	Not approved	3	\$2,870,148	\$12,435,300
Moldova	HIV MARPs	CCM	Not approved	3	\$3,849,298	\$12,491,700

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Mongolia	HIV	CCM	Not approved	4	\$2,218,185	\$7,248,730
Mongolia **	TB (DP + HSS part)	CCM	Approved	2	\$3,696,354	\$9,052,040
Morocco	HIV	CCM	Approved	2	\$14,672,516	\$43,597,600
Morocco	TB	CCM	Approved	2	\$5,014,439	\$10,795,300
Mozambique	HIV	CCM	Not approved	3	\$54,163,105	\$131,214,000
Mozambique	TB	CCM	Not approved	3	\$25,407,092	\$69,822,700
Namibia	HIV	CCM	Not approved	4	\$15,248,614	\$44,292,400
Namibia	TB	CCM	Approved	2	\$12,524,672	\$32,994,200
Nepal	HIV	CCM	Approved	2	\$16,150,553	\$57,273,200
Nicaragua	TB	CCM	Not approved	3	\$4,106,578	\$8,247,600
Niger	HIV	CCM	Not approved	3	€ 30,335,989	€ 73,945,000
Niger	Malaria	CCM	Not approved	3	€ 72,627,052	€ 130,640,000
Niger	TB (DP + HSS part)	CCM	Approved	2B	€ 19,035,383	€ 42,226,000
Nigeria	HIV (DP + HSS part)	CCM	Not approved	4	\$97,491,288	\$383,708,000
Pakistan *	Malaria (DP)	CCM	Approved	2B	\$23,395,667	\$51,516,700



Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Pakistan	Malaria (HSS part)	CCM	Not approved	n/a	\$15,199,740	\$21,594,900
Panama	HIV MARPs	CCM	Approved	2	\$4,202,744	\$10,273,500
Papua NG *	HIV (DP + HSS part)	CCM	Approved	2	\$23,419,727	\$46,697,000
Peru	HIV MARPs	CCM	Approved	2	\$4,999,999	\$12,499,900
Peru	Malaria	CCM	Not approved	3	\$2,835,863	\$7,741,900
Peru	TB	CCM	Not approved	3	\$15,481,203	\$29,837,000
Russian Fed.	TB	CCM	Approved	2B	\$63,472,958	\$126,926,000
Russian Fed.	TB	Sub-CCM	Not approved	4	€ 20,170,145	€ 36,360,000
Sao Tome & P.	HIV	CCM	Approved	2	\$1,279,852	\$2,476,700
Senegal	Malaria	CCM	Approved	2	€ 21,650,781	€ 62,865,000
Senegal * **	TB	CCM	Approved	2	€ 6,335,035	€ 17,460,000
Sierra Leone	Malaria	CCM	Approved	2	\$23,255,609	\$62,649,800
Sierra Leone	TB (DP + HSS part)	CCM	Not approved	3	\$34,333,373	\$77,234,600
Somalia	Malaria (DP + HSS part)	Non-CCM	Approved	2	\$39,333,002	\$84,550,300
Somalia * **	TB	Non-CCM	Approved	2B	\$14,213,393	\$58,380,900

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
South Africa	HIV	CCM	Approved	2	\$128,481,275	\$302,717,000
Sri Lanka	TB (DP + HSS part)	CCM	Not approved	3	\$11,845,852	\$25,088,800
Sudan North	HIV	CCM	Approved	2	\$21,944,538	\$61,919,600
Sudan North	Malaria	CCM	Approved	2B	\$61,256,082	\$182,841,000
Sudan South	HIV	Sub-CCM	Not approved	4	\$65,528,320	\$135,697,000
Sudan South	Malaria	Sub-CCM	Approved	2	\$26,486,653	\$98,618,400
Sudan South	TB	Sub-CCM	Not approved	3	\$16,374,061	\$50,114,000
Swaziland	HIV	CCM	Not approved	3	\$34,723,593	\$89,609,300
Swaziland **	TB	CCM	Approved	2	\$11,202,195	\$39,004,200
Syria *	HIV MARPs	CCM	Approved	2B	\$1,723,169	\$3,396,720
Tajikistan	HIV	CCM	Not approved	3	\$20,521,257	\$64,745,400
Tajikistan	TB	CCM	Not approved	3	\$49,913,253	\$115,418,000
Tanzania	HIV	CCM	Not approved	3	\$50,880,157	\$113,178,000
Tanzania	TB	CCM	Not approved	3	\$33,201,781	\$68,786,100
Thailand	HIV	CCM	Approved	2	\$15,398,249	\$42,088,500

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Thailand *	Malaria	CCM	Approved	2B	\$32,500,432	\$78,378,600
Thailand	TB	CCM	Approved	2	\$12,344,773	\$31,716,800
Timor-Leste	HIV	CCM	Approved	1	\$6,798,682	\$14,254,600
Timor-Leste *	Malaria	CCM	Approved	2B	\$7,170,680	\$22,349,900
Timor-Leste	TB	CCM	Not approved	3	\$2,706,769	\$9,661,900
Togo	HIV	CCM	Not approved	3	€ 6,280,885	€ 16,083,000
Tunisia	HIV MARPs	CCM	Not approved	3	\$4,144,950	\$12,499,300
Uganda	HIV (DP)	CCM	Not approved	n/a	\$55,834,292	\$217,300,000
Uganda	HIV (HSS part)	CCM	Approved	2	\$17,917,965	\$25,251,100
Uganda	Malaria	CCM	Approved	2	\$53,167,057	\$155,963,000
Uganda	TB	CCM	Approved	2	\$10,391,585	\$24,757,100
Ukraine	HIV	CCM	Approved	2	\$95,842,099	\$305,535,000
Uruguay	HIV MARPs	CCM	Approved	2	\$3,953,375	\$9,572,400
Uzbekistan	HIV	CCM	Approved	2	\$9,519,645	\$14,828,300
Vietnam	HIV (DP)	CCM	Not approved	n/a	\$45,071,739	\$188,864,000

Applicant	Disease component	Applicant type	Decision	Category	Cost	
					(Years 1-2)	(Year 3)
Vietnam	HIV (HSS part)	CCM	Approved	2B	\$42,102,165	\$86,636,165
Yemen	HIV (DP + HSS part)	CCM	Not approved	3	\$14,565,766	\$32,312,900
Zambia *	HIV	CCM	Approved	2	\$102,851,986	\$259,216,000
Zanzibar (Tanz.)	TB	CCM	Approved	2	\$2,633,434	\$5,912,900
Zimbabwe	HIV (DP + HSS part)	CCM	Not approved	3	\$118,402,303	\$342,054,000
Zimbabwe	Malaria	CCM	Approved	2	\$14,550,666	\$24,960,500
Zimbabwe	TB	CCM	Not approved	3	\$12,193,205	\$25,507,100
Total – 135 country-based proposals						

\* The TRP-recommended funding has been reduced from the requested amount because the TRP removed certain elements from the proposal.

\*\* These are consolidated proposals. The TRP-recommended funding has been reduced to remove amounts included in the proposals for existing, already funded programmes.

Table 10: Round 10 results for regional applicants

Note: For approved proposals, the costs shown in the last two columns are the amounts recommended by the TRP. For proposals that were not approved, the costs are the amounts requested by the applicant.

Applicant	Disease component	Applicant type	Decision	Category	Cost
					Years 1-2
AMREF (Re Burundi, Ethiopia, Kenya, Tanzania, Uganda)	TB	RO	Not approved	4	\$29,868,200

Applicant	Disease component	Applicant type	Decision	Category	Years 1-2
<b>APN+</b> (Re Bangladesh, Indonesia, Lao PDR, Nepal, Pakistan, Philippines, Viet Nam) *	HIV	RO	Approved	2	\$1,200,000
<b>ASICAL</b> (Re Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay)	HIV MARPs	RO	Not approved	3	\$4,827,281
<b>CONGA</b> (Re Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama)	HIV MARPs	RO	Not approved	4	\$4,506,212
<b>ECSA</b> (Re Zambia, Zimbabwe)	TB	RO	Not approved	3	\$3,322,054
<b>GLIA</b> (Re Burundi, Congo DR, Kenya, Rwanda, Tanzania, Uganda)	HIV MARPs	RO	Not approved	4	\$4,873,647
<b>HIVOS-SA</b> (Re Lesotho, Mauritius, Namibia, South Africa, Swaziland)	HIV	RO	Not approved	4	\$12,130,614
<b>ISEAN-HIVOS</b> (Re Indonesia, Malaysia, Philippines, Timor-Leste)	HIV MARPs	RO	Approved	2B	\$4,767,802
<b>MENAHRA</b> (Re Afghanistan, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Morocco, Oman, West Bank and Gaza, Pakistan, Syria, Tunisia) *	HIV MARPs	RO	Approved	2B	\$3,209,492
<b>Meso</b> (Re Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama)	HIV	RCM	Not approved	3	\$7,868,536
<b>MOZIZA</b> (Re Mozambique, South Africa, Zimbabwe)	Malaria	RCM	Not approved	4	\$12,322,727
<b>OECS</b> (Re Antigua and Barbuda, Dominica, Grenada, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and Grenadines)	HIV	RCM	Not approved	3	\$3,112,877
<b>REDCA+</b> (Re Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama) **	HIV	RO	Approved	2	\$2,366,057
<b>REDLACTRANS</b> (Re Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay)	HIV MARPs	RO	Not approved	3	\$4,994,209
<b>REDTRASEX</b> (Re Argentina, Bolivia, Brazil, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay)	HIV MARPs	RO	Approved	2	\$4,328,974

Total – 15 regional proposals

RO = Regional organisation RCM = Regional coordinating mechanism

\* The TRP-recommended funding has been reduced from the requested amount because the TRP removed certain elements from the proposal.

\*\* This is a consolidated proposal. The TRP-recommended funding has been reduced to remove amounts included in the proposal for existing, already funded programmes.

[Read More](#)

---